Nektar and Puretech make strange bedfellows
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Destiny’s date with a partner
The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.
Seres brings the microbiome back to life
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
